

## Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

**Marco Perez, Antonio Lucena-Cacace, Luis Miguel Marín-Gómez, Javier Padillo-Ruiz, Maria Jose Robles-Frias, Carmen Saez, Rocio Garcia-Carbonero and Amancio Carnero**

Present: Due to an error in proofreading, a research project number was accidentally omitted from the Acknowledgments list.

Correct: The correct numbers are provided below. The authors sincerely apologize for this oversight.

Original article: Oncotarget. 2016; 7(22):33111-24. doi: 10.18632/oncotarget.8880.

### ACKNOWLEDGMENTS

The authors thank the donors and HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13/0010/0056) for the human specimens used in this study. We also thank Jorge Martin-Perez for the generous gift of Src gene. The AC lab was supported by grants from the Spanish Ministry of Economy and Competitiveness, Plan Nacional de I+D+I 2008-2011, Plan Estatal de I+D+I 2013-2016, ISCIII (Fis: [PI10/02164](#), PI12/00137, PI13/02295, PI15/00045, RTICC: RD12/0036/0028) co-funded by FEDER from Regional Development European Funds (European Union), Consejería de Ciencia e Innovación (CTS-1848) and Consejería de Salud of the Junta de Andalucía (PI-0306- 2012 and PI-0096-2014).